Natural Product (NP) Details
General Information of the NP (ID: NP1411) | |||||
---|---|---|---|---|---|
Name |
Theanine
|
||||
Synonyms |
L-Theanine; Theanine; 3081-61-6; Theanin; N-Ethyl-L-glutamine; Suntheanine; (S)-2-Amino-5-(ethylamino)-5-oxopentanoic acid; N5-Ethyl-L-glutamine; L-gamma-Glutamylethylamide; N(5)-ethyl-L-glutamine; N-gamma-Ethyl-L-glutamine; UNII-8021PR16QO; (2S)-2-amino-5-(ethylamino)-5-oxopentanoic acid; CHEBI:17394; L-Glutamic acid ?-(ethylamide); 8021PR16QO; L-Theanine, 98%; N(5)-ethyl-L-glutamine zwitterion; CCRIS 7326; EINECS 221-379-0; NSC 21308; n-ethylglutamine; L-Theamine; MFCD00059653; NSC-21308; HSDB 8166; (+)-Theanine; N?-Ethyl-L-glutamine; H-Glu(NHEt)-OH; PubChem13022; N-?-Ethyl-L-glutamine; Spectrum2_001693; Spectrum3_001137; Spectrum4_001984; Spectrum5_000897; Glutamine, N-gamma-ethyl-; Glutamine, N-ethyl-, L-; BSPBio_002633; KBioGR_002514; SCHEMBL190716; SPECTRUM1505254; SPBio_001646; EBD678; CHEMBL3039113; KBio3_002133; DTXSID80184817; L-glutamic acid -r-monoethylamide; L-Theanine, >=98% (HPLC); BCP28252; ZINC1532828; ANW-26983; CCG-38778; CT0238; s3852; AKOS016842508; AM82649; DB12444; L-Theanine (Ngamma-ethyl-L-glutamine); SDCCGMLS-0066811.P001; NCGC00178565-01; AC-23939; AS-12265; HY-15121; AB0006097; CS-0003777; N2085; C01047; 081T616; A820634; Q909931; SR-05000002409; Q-201330; SR-05000002409-1; (2S)-2-azanyl-5-(ethylamino)-5-oxidanylidene-pentanoic acid; C6B5A580-D410-4464-ADB8-543860137D4C; L-Theanine, United States Pharmacopeia (USP) Reference Standard
Click to Show/Hide
|
||||
Species Origin | Theaceae ... | Click to Show/Hide | |||
Theaceae | |||||
Disease | Attention deficit hyperactivity disorder [ICD-11: 6A05] | Phase 2 | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C7H14N2O3
|
||||
PubChem CID | |||||
Canonical SMILES |
CCNC(=O)CCC(C(=O)O)N
|
||||
InChI |
1S/C7H14N2O3/c1-2-9-6(10)4-3-5(8)7(11)12/h5H,2-4,8H2,1H3,(H,9,10)(H,11,12)/t5-/m0/s1
|
||||
InChIKey |
DATAGRPVKZEWHA-YFKPBYRVSA-N
|
||||
CAS Number |
CAS 3081-61-6
|
||||
ChEBI ID | |||||
Herb ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Doxorubicin | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | M5076 | CVCL_3997 | Mouse ovarian histiocytic sarcoma | Mus musculus | ||
In-vivo Model | M5076 ovarian sarcoma (1 * 106 cells/mouse) were s.c. transplanted onto the backs of BDF1 mice. | |||||
Experimental
Result(s) |
Theanine increased not only the antitumor activity on primary tumor but also the metastasis-suppressive efficacy of doxorubicin. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Interleukin-6 (IL6) | Molecule Info | [3] | |
KEGG Pathway | Cytokine-cytokine receptor interaction | Click to Show/Hide | ||
2 | HIF-1 signaling pathway | |||
3 | FoxO signaling pathway | |||
4 | PI3K-Akt signaling pathway | |||
5 | Toll-like receptor signaling pathway | |||
6 | NOD-like receptor signaling pathway | |||
7 | Cytosolic DNA-sensing pathway | |||
8 | Jak-STAT signaling pathway | |||
9 | Hematopoietic cell lineage | |||
10 | TNF signaling pathway | |||
11 | Intestinal immune network for IgA production | |||
12 | Non-alcoholic fatty liver disease (NAFLD) | |||
13 | Prion diseases | |||
14 | Salmonella infection | |||
15 | Pertussis | |||
16 | Legionellosis | |||
17 | Chagas disease (American trypanosomiasis) | |||
18 | African trypanosomiasis | |||
19 | Malaria | |||
20 | Amoebiasis | |||
21 | Tuberculosis | |||
22 | Hepatitis B | |||
23 | Measles | |||
24 | Influenza A | |||
25 | HTLV-I infection | |||
26 | Herpes simplex infection | |||
27 | Pathways in cancer | |||
28 | Transcriptional misregulation in cancer | |||
29 | Inflammatory bowel disease (IBD) | |||
30 | Rheumatoid arthritis | |||
31 | Graft-versus-host disease | |||
32 | Hypertrophic cardiomyopathy (HCM) | |||
NetPath Pathway | IL1 Signaling Pathway | Click to Show/Hide | ||
2 | TWEAK Signaling Pathway | |||
3 | TCR Signaling Pathway | |||
4 | IL2 Signaling Pathway | |||
5 | IL4 Signaling Pathway | |||
6 | TGF_beta_Receptor Signaling Pathway | |||
7 | TNFalpha Signaling Pathway | |||
8 | Alpha6Beta4Integrin Signaling Pathway | |||
9 | TSLP Signaling Pathway | |||
10 | Leptin Signaling Pathway | |||
11 | RANKL Signaling Pathway | |||
12 | IL5 Signaling Pathway | |||
Panther Pathway | Interleukin signaling pathway | Click to Show/Hide | ||
Pathway Interaction Database | LPA receptor mediated events | Click to Show/Hide | ||
2 | IL27-mediated signaling events | |||
3 | Validated transcriptional targets of AP1 family members Fra1 and Fra2 | |||
4 | SHP2 signaling | |||
5 | Glucocorticoid receptor regulatory network | |||
6 | amb2 Integrin signaling | |||
7 | ATF-2 transcription factor network | |||
8 | AP-1 transcription factor network | |||
9 | IL6-mediated signaling events | |||
10 | IL23-mediated signaling events | |||
Reactome | Interleukin-6 signaling | Click to Show/Hide | ||
2 | MAPK3 (ERK1) activation | |||
3 | MAPK1 (ERK2) activation | |||
4 | Senescence-Associated Secretory Phenotype (SASP) | |||
WikiPathways | Toll-like receptor signaling pathway | Click to Show/Hide | ||
2 | SIDS Susceptibility Pathways | |||
3 | TCR Signaling Pathway | |||
4 | Senescence and Autophagy in Cancer | |||
5 | Cytokines and Inflammatory Response | |||
6 | IL-6 signaling pathway | |||
7 | Myometrial Relaxation and Contraction Pathways | |||
8 | Hematopoietic Stem Cell Differentiation | |||
9 | Differentiation Pathway | |||
10 | Interleukin-6 signaling | |||
11 | Spinal Cord Injury | |||
12 | Adipogenesis | |||
13 | TNF alpha Signaling Pathway | |||
14 | TSLP Signaling Pathway | |||
15 | TWEAK Signaling Pathway | |||
16 | Folate Metabolism | |||
17 | Vitamin B12 Metabolism | |||
18 | Selenium Micronutrient Network | |||
19 | Regulation of toll-like receptor signaling pathway |